Please assess the completion status of the following clinical trial:

Trial Title: Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 24 weeks 0 days-28weeks 6 days by best obstetrical estimate~* \<72 h age~* Positive pressure ventilation for at least 1 hour duration during the first 72 hours of life~* Presence of indwelling intravenous line for drug administration~Exclusion Criteria:~* Any patient judged to be non-viable or for whom withdrawal of life support is planned~* Patients with major lethal congenital anomalies~* Triplets or higher order multiples~* Patients delivered for maternal indications (low risk of Ureaplasma colonization)~* Patients with EKG QT interval corrected for heart rate (Qtc) ≥ 450 ms~* Patients with significant hepatic impairment (direct bilirubin \>1.5 mg/dL)~* Patients exposed to other systemic macrolide~* Patients with clinically suspected Ureaplasma central nervous system (CNS) infection or other confirmed bacterial/viral infection~* Patients participating in other clinical trials involving investigational products.

- Gender: ALL
- Minimum Age: 2 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Placebo (5% dextrose) (Type: PLACEBO_COMPARATOR): Placebo
- Azithromycin (Type: EXPERIMENTAL): Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).